These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 11422747)

  • 1. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
    Koziolek MJ; Riess R; Geiger H; Thévenod F; Hauser IA
    Kidney Int; 2001 Jul; 60(1):156-66. PubMed ID: 11422747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.
    García del Moral R; O'Valle F; Andújar M; Aguilar M; Lucena MA; López-Hidalgo J; Ramírez C; Medina-Cano MT; Aguilar D; Gómez-Morales M
    Am J Pathol; 1995 Feb; 146(2):398-408. PubMed ID: 7856751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of tissue factor (TF) in calcineurin inhibitor-induced nephrotoxicity and rejection--implications for development of a possible diagnostic marker.
    Osterholm C; Veress B; Simanaitis M; Hedner U; Ekberg H
    Transpl Immunol; 2005 Dec; 15(2):165-72. PubMed ID: 16412961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity.
    Pankewycz OG; Miao L; Isaacs R; Guan J; Pruett T; Haussmann G; Sturgill BC
    Kidney Int; 1996 Nov; 50(5):1634-40. PubMed ID: 8914030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
    Hauser IA; Schaeffeler E; Gauer S; Scheuermann EH; Wegner B; Gossmann J; Ackermann H; Seidl C; Hocher B; Zanger UM; Geiger H; Eichelbaum M; Schwab M
    J Am Soc Nephrol; 2005 May; 16(5):1501-11. PubMed ID: 15772250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts.
    Frank K; Zeier M; Gross ML; Waldherr R; Ritz E; Amann K
    Nephrol Dial Transplant; 2006 May; 21(5):1365-72. PubMed ID: 16449275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modifying cyclosporine associated renal allograft dysfunction.
    Mohapatra N; Vanikar AV; Patel RD; Trivedi HL
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):770-4. PubMed ID: 19736471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells.
    Hauser IA; Koziolek M; Hopfer U; Thévenod F
    Kidney Int; 1998 Oct; 54(4):1139-49. PubMed ID: 9767529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits.
    del Moral RG; Andujar M; Ramírez C; Gómez-Morales M; Masseroli M; Aguilar M; Olmo A; Arrebola F; Guillén M; García-Chicano MJ; Nogales FF; O'Valle F
    Am J Pathol; 1997 Dec; 151(6):1705-14. PubMed ID: 9403721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and structural consequences of early renal allograft injury.
    Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
    Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: evidence for improved kidney graft outcome.
    Savikko J; Teppo AM; Taskinen E; von Willebrand E
    Transpl Immunol; 2014 Sep; 31(3):145-51. PubMed ID: 25158212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.
    Khanna A; Plummer M; Bromberek C; Bresnahan B; Hariharan S
    Kidney Int; 2002 Dec; 62(6):2257-63. PubMed ID: 12427154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection.
    Gaweco AS; Mitchell BL; Lucas BA; McClatchey KD; Van Thiel DH
    Kidney Int; 1999 Apr; 55(4):1543-52. PubMed ID: 10201021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney-specific deletion of multidrug resistance-related protein 2 does not aggravate acute cyclosporine A nephrotoxicity in rats.
    Mähler N; Freyer M; Kauschke R; Schlüter T; Steinbach AC; Oswald S; Miehe B; Krebs A; Rettig R; Grisk O
    Pharmacogenet Genomics; 2012 Jun; 22(6):408-20. PubMed ID: 21869731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
    Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
    Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
    Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
    Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.
    Solez K; Vincenti F; Filo RS
    Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.